Proceeds will be used to support preclinical validation of the EDIT platform for the development of durable, safe, and affordable in vivo gene therapies.

EDIT is used to simultaneously deliver an RNA sequence that encodes saliogase, a mammalian-derived enzyme, with a DNA sequence of any length to cells of interest via lipid nanoparticles. Transiently expressed saliogase integrates the supplied DNA into a precise, defined location in the recipient genome without the need for homologous recombination.

The company will initially focus on the development of its lead programs in familial hypercholesterolemia and inherited macular degeneration.

The series A financing round was led by PBM Capital. In conjunction with the financing, SalioGen has strengthened its board of directors and its scientific advisory board.

Notch nabs $85M in funding for stem cell-based cell therapies
Notch Therapeutics has closed $85 million in series A financing to continue the development of its portfolio of induced pluripotent stem cell-derived...

Startup Ensoma launches with gene therapy vector platform
A new genomic medicine startup called Ensoma made its corporate debut this week, raising $70 million in financing and entering into a strategic collaboration...

Global Genes produces series on gene therapy, editing
Rare disease patient advocacy organization Global Genes will publish a multimedia series about advances in gene therapy and gene editing technology throughout...

BioLife Solutions invests in cell and gene therapy products
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, along with innovation accelerator partner Casdin Capital, have invested in...